NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Hoffmann-La Roche
Conditions: Relapsing Multiple Sclerosis
Interventions: Interferon beta-1a, Ocrelizumab-matching placebo, Ocrelizumab, Interferon beta-1a-matching placebo
Countries: United States, Argentina, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada
This randomized, double-blind, double-dummy, parallel-group study will evaluate the efficacy and safety of ocrelizumab in comparison with interferon beta-1a (Rebif) in participants with relapsing multiple sclerosis. Participants will be randomized to receive either ocrelizumab 600 mg or matching placebo intravenous (IV) as 300 mg infusions on Days 1 and 15 for the first dose and as a single infusion of 600 mg for all subsequent infusions every 24 weeks, with placebo injections matching interferon beta-1a SC three times per week; or interferon beta-1a 44 mcg SC injections three times per week (with placebo infusions matching ocrelizumab infusions every 24 weeks).
Sex: ALL
Age: 18 Years to 55 Years
Healthy volunteers: No
Study type: INTERVENTIONAL
Inclusion Criteria: * Diagnosis of multiple sclerosis, in accordance with the revised McDonald criteria (2010) * At least 2 documented clinical attacks within the last 2 years prior to screening or one clinical attack in the years prior to screening (but not within 30 days prior to screening) * Neurologic stability for greater than or equal to (\>/=) 30 days prior to both screening and baseline * Expanded Disability Status Scale (EDSS) score 0 to 5.5 inclusive Exclusion Criteria: * Primary progressive multiple sclerosis * Disease duration of more than 10 years in patients with EDSS score less than or equal to (\</=) 2.0 at screening * Contraindications for MRI * Known presence of other neurological disorders which may mimic multiple sclerosis * Pregnancy or lactation * Requirement for chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study * History of or currently active primary or secondary immunodeficiency * History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies * Active infection, or history of or known presence of recurrent or chronic infection (for example, hepatitis B or C, Human Immunodeficiency Virus \[HIV\], syphilis, tuberculosis) * History of progressive multifocal leukoencephalopathy * Contraindications to or intolerance of oral or IV corticosteroids * Contraindications to Rebif or incompatibility with Rebif use
- Phoenix, Arizona, United States
- Scottsdale, Arizona, United States
- Tucson, Arizona, United States
- Long Beach, California, United States
- Palo Alto, California, United States
- Denver, Colorado, United States
- Fort Collins, Colorado, United States
- Fairfield, Connecticut, United States
- Hollywood, Florida, United States
- Miami, Florida, United States
- Orlando, Florida, United States
- Sarasota, Florida, United States
- Tampa, Florida, United States
- Atlanta, Georgia, United States
- Indianapolis, Indiana, United States
- Kansas City, Kansas, United States
- Prairie Village, Kansas, United States
- Lexington, Kentucky, United States
- Wellesley, Massachusetts, United States
- Worcester, Massachusetts, United States
- Ann Arbor, Michigan, United States
- Detroit, Michigan, United States
- Golden Valley, Minnesota, United States
- Newark, New Jersey, United States
- Teaneck, New Jersey, United States
- Teaneck, New Jersey, United States
- Toms River, New Jersey, United States
- Latham, New York, United States
- New York, New York, United States
- Patchogue, New York, United States
- + 135 more on CT.gov